{"schema_version":"secwatch.filing_event.v1","accession":"0001079973-23-001602","form_type":"8-K","ticker":"CFOR","cik":"0001293818","company_name":"CapForce Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.549343+00:00","generated_at":"2026-06-08T03:14:54.894298+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"OpGen Q3 revenue $0.7M; subsidiaries Curetis & Ares Genetics file insolvency, going concern doubt","bullets":["Total revenue Q3 2023 $0.70M vs $0.45M; nine-month $2.35M vs $1.89M.","Cash and equivalents $0.29M at Sep 30; subsequent financing raised ~$3.06M but substantial doubt about going concern.","Subsidiaries Curetis GmbH and Ares Genetics GmbH filed for insolvency Nov 6, 2023 under German/Austrian laws.","OpGen reduced U.S. headcount from 23 to 6; discontinued Acuitas AMR Gene Panel test.","Total operating expenses Q3 2023 $4.26M vs $13.96M (incl. $6.98M goodwill impairment in prior year)."],"urls":{"canonical":"https://secwatch.observer/filing/0001079973-23-001602","json":"https://secwatch.observer/filing/0001079973-23-001602.json","markdown":"https://secwatch.observer/filing/0001079973-23-001602.md","text":"https://secwatch.observer/filing/0001079973-23-001602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/0001079973-23-001602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/opgen_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:14:54.894298+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5d2f3a6ea62fd6f209a663dd167f8bbbfa20307c","claim":"CapForce Inc. reported third quarter 2023 results: revenue approximately $0.70 million.","evidence_excerpt":"its third quarter 2023 financial and operating results. Third Quarter 2023 Financial Results of OpGen, Inc. · Total revenue for the third quarter of 2023 was approximately $0.70 million compared to the Company’s revenue of approximately $0.45 million in the third quarter of 2022. Total revenue for the nine months ended September 30, 2023 was approximately $2.35","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1293818/000107997323001602/0001079973-23-001602-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter 2023"},{"label":"Revenue","value":"approximately $0.70 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}